The Bucks will be without star Damian Lillard for the foreseeable future. The point guard was diagnosed with a deep vein thrombosis in his calf and has been ruled out indefinitely. Lillard has ...

Crews went through a manhole to rescue a woman who was found trapped in a storm drain in Southern California several days after she was reported missing, officials said. Yafang Zhou, 59 ...

BELLA trial evaluates relacorilant, nab-paclitaxel, and Avastin in platinum-resistant ovarian cancer patients across multiple regions. Phase 3 ROSELLA trial showed relacorilant improved ...

The development of antibody-drug conjugates (ADCs) remains a central theme in ongoing research within the realm of ovarian cancer, and work examining different targets and sequencing considerations ...

Allegations that Ascension Parish crews did drainage ditch work along a private road have led to the firing of two government employees — with one council member calling the sequence of events ...

A new drug is showing promise in tackling treatment-resistant ovarian cancer. Relacorilant, the drug tested in a phase 3 ROSELLA trial with Corcept Therapeutics in California, was found to improve ...

Many countries have tried to emulate this model of science-led growth, and to stop the ‘brain drain’ of talent to better-resourced laboratories in the United States. Now, the actions of the US ...

Results from Corcept’s Phase 2 trial of relacorilant in patients with platinum-resistant ovarian cancer were published in the Journal of Clinical Oncology in June 2023. The ROSELLA trial ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to chemotherapy alone. The biopharma intends to take the phase 3 data ...

(Reuters) -Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type of ovarian cancer in a late-stage trial. The company's ...

Relacorilant in combination with nab-paclitaxel yielded higher PFS and OS in patients with platinum-resistant ovarian cancer vs nab-paclitaxel alone. Relacorilant plus nab-paclitaxel (Abraxane) ...

Mirvetuximab soravtansine-gynx (Elahere) showed a significant survival benefit compared with investigator’s choice chemotherapy when used for the treatment of patients with folate receptor alpha (FRα) ...